About KT-579 KT-579 is an investigational, first-in-class, oral degrader of IRF5, a genetically validated transcription factor and master regulator of immunity. KT-579 has the potential to modulate ...
Q3 2026 VIZZ® product sales increased 50% over prior quarter, with strong momentum continuing into Q4 as consumer awareness broadens and telehealth adoption increases Strategic reorganization to ...
Nordic Naturals, the #1 selling omega-3 brand in the U.S.‡, today announced it will be a featured partner and brand presenter at the Eudēmonia Summit, a science-based wellness and longevity show ...
In November 2025, a multi-center, open-label, randomized controlled Phase 3 clinical study to compare JS001sc and toripalimab injection in combination with chemotherapy for the first-line treatment of ...
The Emory University Center for Neurodegenerative Diseases and Emory ALS Center researchers initially profiled plasma from 632 ALS patients and 160 healthy controls using NULISAseq™ CNS and ...
A live webcast of the conference call may also be found on the “ News & Events ” page in the Investors section of the Mineralys Therapeutics website. About Mineralys Mineralys Therapeutics is a ...
MARIETTA, Ga., Oct. 28, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced operating and financial results for the third quarter of 2026.
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease.
A live and archived webcast of the fireside chat will be available in the "Investor Relations" section of the Ceribell website at https://investors.ceribell.com/ .
Details for the conference call can be found below: Please call the conference telephone number or log on to the web access link five minutes prior to the start time. A replay of the call will remain ...
Sovleplenib is a novel, selective inhibitor of Syk for once daily oral administration. Syk is a major component in B-cell receptor and FcR signaling and is an established target for the treatment of ...
On July 30, 2026, the Company completed the continuance of its parent entity from British Columbia, Canada to Nevada, United States (the “Continuance”), following shareholder approval on June 24, 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results